Smith & Nephew


Sports medicine leads a good Q3 showing

26/11/19 -"Smith & Nephew reported Q3 19 top-line growth of 4% on an underlying basis – driven by Sports Medicine Joint Repair (+12.2%), Advanced Wound Devices (+15.4%), Knee Implants (+4.6%) and ENT ..."

Pages
52
Language
English
Published on
26/11/19
You may also be interested by these reports :
02/07/20
The increase in our NAV valuation is a result of an increase in our estimates, which is driven by the increased activity/focus in the vaccine space, ...

19/06/20
Elekta (Buy, Sweden), the world’s No.2 player (market share c.30%) in the $7.5bn oligopolistic radiation therapy oncology space, was dumped by ...

18/06/20
Benefiting from the gradual re-opening of economies, conditions within the hearing healthcare market have improved and Demant is now operating at a ...

09/06/20
Once the darling of COVID-19 lockdown times, the Health sector (ex Pharma) has gone into reverse now that the risk needle has moved by 180°. Sure ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO